Cart
sales@molnova.com
NBD-14107
CAS No. 2086328-94-9
NBD-14107( NBD14107 )
Catalog No. M13251 CAS No. 2086328-94-9
A potent HIV-1 entry inhibitor that blocks the gp120-CD4 interaction.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNBD-14107
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent HIV-1 entry inhibitor that blocks the gp120-CD4 interaction.
-
DescriptionA potent HIV-1 entry inhibitor that blocks the gp120-CD4 interaction; exhibits antiviral activity against a large panel of HIV-1 Env-pseudotyped viruses representing diverse subtypes of clinical isolates with mean EC50 of 0.49 uM; also inhibits HIV-1 RT with IC50 of 8.4 uM; exhibits improving the potency, toxicity, and ADMET profile compared with NBD-14010.HIV Preclinical.
-
In Vitro——
-
In Vivo——
-
SynonymsNBD14107
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2086328-94-9
-
Formula Weight412.84
-
Molecular FormulaC17H15ClF2N4O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameN-(2-amino-1-(5-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(4-chloro-3,5-difluorophenyl)-1H-pyrrole-2-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Curreli F, et al. J Med Chem. 2017 Apr 13;60(7):3124-3153.
molnova catalog
related products
-
Bictegravir
Bictegravir (GS 9883) is a novel potent HIV-1 integrase (IN) that specifically targets IN strand transfer activity with IC50 of 7.5 nM.
-
Feruloyltyramine
NTF is likely to inhibit COX enzymes, thereby suppressing P-selectin expression on platelets, is a platelet aggregation inhibitor.
-
HIV-IN-6
HIV-IN-6 is an HIV viral inhibitor that inhibits the replication of the HIV virus.HIV-IN-6 has anti-HIV viral activity and works by targeting Src family kinases (SFK) (e.g., Hck) that interact with the viral Nef protein.
